Jefferies Maintains an 'Underperform' AMAG Pharmaceuticals (AMAG); Still Sees Roughly Breakeven for FY12; Ongoing Strategic Review

Jefferies maintains an 'Underperform' AMAG Pharmaceuticals (NASDAQ: AMAG) price target of $12.00.

Analyst, Eun K. Yang, said, "There was no surprise on the 4Q11 call as 4Q results and FY12 guidance were preannounced in early-January. We view FY12 Feraheme sales guidance of $53M-$57M as achievable. Exploring strategic options is still under way. While timing for such outcome is uncertain, estimated YE12 cash ($11.50/sh) would provide valuation support."

For an analyst ratings summary and ratings history on AMAG Pharmaceuticals click here. For more ratings news on AMAG Pharmaceuticals click here.

Shares of AMAG Pharmaceuticals closed at $16.09 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery